Remedium Bio secured $10 million in Series A funding to advance a platform technology that converts subcutaneous fat tissue into sustained protein-production sites, reducing treatment frequency from multiple injections to single administrations with adjustable dosing. The approach targets cardiometabolic and chronic disease management through controlled gene expression.
Key Points
- Platform uses adipocytes as durable protein-production sites via single injection
- Adjustable expression enables dose optimization and multi-year therapeutic benefit
- Targets replacement of frequent subcutaneous biologics for chronic disease management
Longevity Analysis
This technology addresses a fundamental challenge in chronic disease management: the burden of frequent dosing and its effects on treatment adherence and metabolic burden. By converting the body's own adipose tissue into a controllable protein factory, the approach reduces both systemic stress and the cumulative physiological cost of repeated injections. For chronic cardiometabolic conditions—where sustained, stable therapeutic levels are critical—this shift from external administration to internally sustained production could improve efficacy while lowering the interference from treatment protocols themselves. The adjustable dosing component is particularly relevant: it enables real-time calibration of therapeutic levels without reinitiation, reducing the oscillating stress-response patterns typical of intermittent dosing schedules.
Original published by LT Wire.